



REFERENCE NO.: 2015 - 06437

OWNER:

MARCIO LUIS DE MEDEROS **ARMANDO ROSSI 90** BR-95052060 INTERLAGOS, CAXIAS DO SUL

BRAZIL

NAME/LABEL:

PANTUFA MC DO SULFOCK

SPECIES: DOG

BREED: BRAZILIAN TERRIER

SEX: FEMALE

MICROCHIP NO .: NOT PROVIDED TATOO NO.: NOT PROVIDED **PEDIGREE NO.:** RSA/10/03258

GENETIC REPORT

SAMPLE:

BUCCAL SWAB

SAMPLE TAKEN BY: ANDREA R. LUCHESI VALIATI, DVM

REQUESTED TEST:

MUCOPOLYSACCHARIDOSIS VII (MPS VII)

RESULT:

CLEAR

COMMENT:

The test examines presence or absence of GUSB gene mutation (c.886C>T) described as the cause of mucopolysaccharidosis VII (MPS VII) in Brazilian Terrier. The disease is characterized by severe skeletal deformities clinically detectable within the first month of life. GUSB gene defect is inherited as an autosomal recessive trait.

Regarding to the presence of tested mutation animals are classified in three groups:

- Clear (wt/wt) mutation is not present, normal genotype
- Carrier (mut/wt) one of two alleles carries tested mutation, disease is not clinically manifested
- Affected (mut/mut) both alleles carry tested mutation, disease is clinically manifested

For each group different breeding strategies should be followed. Breeding of affected and carrier animals should be avoided. If particularly valuable animal is classified as affected, it should be bred only with clear animal. In such case, all first generation siblings will be carriers. If a carrier is bred with clear animal, 50% of siblings are expected to be clear. In case two carriers are bred, 25% of siblings are expected to be clear and 50% are expected to be carriers. However, 25% of siblings are expected to be affected, therefore such breeding practice is discouraged.



MARIBOR, 14.12.2015

Results are valid for laboratory analysed samples only. Accuracy of the data about animal identity is the sole responsibility of the customer/owner. Laboratory is not responsible for false results which arise due to inaccurate animal identity data, false sample labels etc. To the extent the law allows, the maximal compensation for potential false result is limited to the invoiced amount. With the test it is not possible to rule out the presence of other genetic changes which might affect the development of the disease. Testing is performed according to the latest scientific knowledge.